Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance) Journal Article

Authors: Bluethmann, S. M.; Alfano, C. M.; Clapp, J. D.; Luta, G.; Small, B. J.; Hurria, A.; Cohen, H. J.; Sugarman, S.; Muss, H. B.; Isaacs, C.; Mandelblatt, J. S.
Article Title: Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)
Abstract: Purpose: To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ (“older”). Methods: Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011. Eligible survivors (n = 1280) completed baseline interviews; follow-up was conducted annually for up to 7 years. Survivors with estrogen-receptor-positive (ER+) cancers who initiated hormonal therapy (n = 990) were included. Self-reported cognitive function was measured using the EORTC-QLQ30 scale; a difference of eight points on the 0–100 scale was considered clinically significant. Based on varying rates of discontinuation over time, discontinuation was evaluated separately for three time periods: early (<1 year); midpoint (1–3 years); and late discontinuation (>3–5 years). Cox models for each time period were used to evaluate the effects of cognition immediately preceding discontinuation, controlling for age, chemotherapy, and other covariates. Results: Survivors were 65–91 years old (mean 72.6 years), and 79% had stages 1 or 2A disease. Overall, 43% discontinued hormonal therapy before 5 years. Survivors who reported lower cognitive function in the period before discontinuation had greater hazards of discontinuing therapy at the treatment midpoint (HR 1.22 per 8-point difference, CI 1.09–1.40, p < 0.001), considering covariates, but cognition was not related to discontinuation in the other periods. Conclusions: Self-reported cognitive problems were a significant risk factor for discontinuation of hormonal therapy 1–3 years post-initiation. Additional research is needed on the temporality of cognitive effects and hormonal therapy to support survivorship care needs of older survivors. © 2017, Springer Science+Business Media, LLC.
Keywords: adjuvant therapy; survivorship; cognition; aging; cognitive function
Journal Title: Breast Cancer Research and Treatment
Volume: 165
Issue: 3
ISSN: 0167-6806
Publisher: Springer  
Date Published: 2017-10-01
Start Page: 677
End Page: 686
Language: English
DOI: 10.1007/s10549-017-4353-y
PROVIDER: scopus
PUBMED: 28653250
PMCID: PMC5709158
Notes: Article -- Export Date: 4 October 2017 -- Source: Scopus
Citation Impact
MSK Authors